Physician profile
James J Meeks
NPI 1740608983
$1,645.60
in general payments reported to CMS, 2019-2025
18 companies · $83.42 in 2025
The $83.42 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.32 · 2021: $15.56 · 2022: $302 · 2023: $713 · 2024: $517 · 2025: $83.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,312.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $402.83 | 2022-2025 | |
| Neos Therapeutics, LP | $171.56 | 2023-2024 | Adzenys Xr-Odt |
| Otsuka America Pharmaceutical, INC. | $167.54 | 2021-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $153.27 | 2022-2024 | Spravato |
| Lundbeck LLC | $130.24 | 2022-2023 | Rexulti |
| Corium, LLC | $103.92 | 2022-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $103.58 | 2023-2024 | Hetlioz, Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.42 | 2022-2024 | Caplyta |
| Alkermes, INC. | $81.83 | 2024-2025 | Aristada, Lybalvi |
| Idorsia Pharmaceuticals US INC | $66.10 | 2023-2024 | Quviviq |
| Axsome Therapeutics, INC. | $49.36 | 2023-2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $25.35 | 2023 | Trintellix |
| Supernus Pharmaceuticals, INC. | $23.38 | 2023 | Qelbree |
| Tris Pharma INC | $23.37 | 2023 | Dyanavel Xr |
| Neuronetics, INC. | $17.20 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $15.32 | 2019 | |
| Novo Nordisk INC | $15.28 | 2023 | Wegovy |
| Stimwave Technologies Incorporated | $10.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Meeks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.